Literature DB >> 7452666

Amino acid and dipeptide derivatives of daunorubicin. 2. Cellular pharmacology and antitumor activity on L1210 leukemic cells in vitro and in vivo.

R Baurain, M Masquelier, D Deprez-De Campeneere, A Trouet.   

Abstract

The accumulation of amino acid and dipeptide derivatives of DNR has been studied in vitro on L1210 cells. Only Leu-DNR reaches accumulation levels close to DNR, while Val-DNR, Ile-DNR, and Leu-Leu-DNR reach intermediate values. Intracellular DNR was found when the L1210 cells were incubated in the presence of DNR, Leu-Leu-DNR, Leu-Ala-DNR, and Leu-DNR. The cytostatic activity of the derivatives in vitro on L1210 cells cannot be correlated with their uptake or conversion into DNR. At equitoxic doses given iv on the iv inoculated form of L1210 leukemia, all the derivatives are less active than DNR. When given iv on the sc inoculated L1210 leukemia, Leu-DNR, Ala-Leu-DNR and Leu-Leu-DNR are much more active than DNR with a striking increase in ILS and reduction of tumor progression. The superiority of those compounds could be due to their greater hydrophobicity and to their hydrolysis in situ by enzymes secreted by tumor cells or present on the tumor cells surface.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7452666     DOI: 10.1021/jm00185a004

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  9 in total

1.  Antibody-penicillin-V-amidase conjugates kill antigen-positive tumor cells when combined with doxorubicin phenoxyacetamide.

Authors:  D E Kerr; P D Senter; W V Burnett; D L Hirschberg; I Hellström; K E Hellström
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

2.  Metabolism of daunorubicin in sensitive and resistant Ehrlich ascites tumor cells. Determination by high pressure liquid chromatography.

Authors:  D Londos-Gagliardi; R Baurain; J Robert; G Aubel-Sadron
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

3.  Platform to Discover Protease-Activated Antibiotics and Application to Siderophore-Antibiotic Conjugates.

Authors:  Jonathan H Boyce; Bobo Dang; Beatrice Ary; Quinn Edmondson; Charles S Craik; William F DeGrado; Ian B Seiple
Journal:  J Am Chem Soc       Date:  2020-12-10       Impact factor: 15.419

4.  The feasibility of enzyme targeted activation for amino acid/dipeptide monoester prodrugs of floxuridine; cathepsin D as a potential targeted enzyme.

Authors:  Yasuhiro Tsume; Gordon L Amidon
Journal:  Molecules       Date:  2012-03-26       Impact factor: 4.411

5.  Protease-activated drug development.

Authors:  Ki Young Choi; Magdalena Swierczewska; Seulki Lee; Xiaoyuan Chen
Journal:  Theranostics       Date:  2012-02-08       Impact factor: 11.556

Review 6.  Strategies for Dodging the Obstacles in CAR T Cell Therapy.

Authors:  Pooria Safarzadeh Kozani; Pouya Safarzadeh Kozani; Fatemeh Rahbarizadeh; Shahryar Khoshtinat Nikkhoi
Journal:  Front Oncol       Date:  2021-04-01       Impact factor: 6.244

Review 7.  Peptide-based delivery of therapeutics in cancer treatment.

Authors:  Timothy Samec; Jessica Boulos; Serena Gilmore; Anthony Hazelton; Angela Alexander-Bryant
Journal:  Mater Today Bio       Date:  2022-03-30

8.  Preclinical development of carrier-free prodrug nanoparticles for enhanced antitumor therapeutic potential with less toxicity.

Authors:  Man Kyu Shim; Suah Yang; Jooho Park; Jun Sik Yoon; Jinseong Kim; Yujeong Moon; Nayeon Shim; Mihee Jo; Yongwhan Choi; Kwangmeyung Kim
Journal:  J Nanobiotechnology       Date:  2022-10-04       Impact factor: 9.429

9.  The anti-tumour effects of the prodrugs N-l-leucyl-doxorubicin and vinblastine-isoleucinate in human ovarian cancer xenografts.

Authors:  E Boven; H R Hendriks; C A Erkelens; H M Pinedo
Journal:  Br J Cancer       Date:  1992-12       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.